{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:57:55Z","timestamp":1785448675209,"version":"3.56.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"DOI":"10.1038\/s41440-026-02753-y","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:09:01Z","timestamp":1785402541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early plasma volume and interstitial fluid responses to SGLT2 inhibitor, loop diuretics, and their combination in chronic kidney disease"],"prefix":"10.1038","author":[{"given":"Kosuke","family":"Yuyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Asakura-Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Morinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Akimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"2753_CR1","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1093\/ndt\/gfae060","volume":"39","author":"V Vallon","year":"2024","unstructured":"Vallon V. How can inhibition of glucose and sodium transport in the early proximal tubule protect the cardiorenal system? Nephrol Dial Transpl. 2024;39:1565\u201373.","journal-title":"Nephrol Dial Transpl"},{"key":"2753_CR2","doi-asserted-by":"publisher","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","volume":"306","author":"T Rieg","year":"2014","unstructured":"Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Ren Physiol. 2014;306:F188\u201393.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2753_CR3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41440-023-01220-2","volume":"46","author":"T Masuda","year":"2023","unstructured":"Masuda T, Nagata D. Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors: novel insight for better cardio-renal outcomes in chronic kidney disease. Hypertens Res. 2023;46:1195\u2013201.","journal-title":"Hypertens Res"},{"key":"2753_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2025.20834","volume":"335","author":"BL Neuen","year":"2026","unstructured":"Neuen BL, Fletcher RA, Anker SD, Bhatt DL, Butler J, Cherney DZI, et al. SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis. JAMA. 2026;335:233\u201344.","journal-title":"JAMA"},{"key":"2753_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"2753_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","volume":"20","author":"KM Hallow","year":"2018","unstructured":"Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diab Obes Metab. 2018;20:479\u201387.","journal-title":"Diab Obes Metab"},{"key":"2753_CR7","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3390\/diagnostics14111194","volume":"14","author":"M Asakura-Kinoshita","year":"2024","unstructured":"Asakura-Kinoshita M, Masuda T, Oka K, Ohara K, Miura M, Morinari M, et al. Sodium\u2013glucose cotransporter 2 inhibitor combined with conventional diuretics ameliorate body fluid retention without excessive plasma volume reduction. Diagnostics. 2024;14:1194.","journal-title":"Diagnostics"},{"key":"2753_CR8","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1038\/s41440-024-01893-3","volume":"47","author":"T Masuda","year":"2024","unstructured":"Masuda T, Yoshida M, Onaka T, Nagata D. Water and sodium conservation response induced by SGLT2 inhibitor ipragliflozin in Dahl salt-sensitive hypertensive rats. Hypertens Res. 2024;47:3173\u201381.","journal-title":"Hypertens Res"},{"key":"2753_CR9","doi-asserted-by":"publisher","first-page":"F653","DOI":"10.1152\/ajprenal.00143.2018","volume":"315","author":"T Masuda","year":"2018","unstructured":"Masuda T, Watanabe Y, Fukuda K, Watanabe M, Onishi A, Ohara K, et al. Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat. Am J Physiol Ren Physiol. 2018;315:F653\u201364.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2753_CR10","first-page":"1","volume":"1","author":"T Masuda","year":"2017","unstructured":"Masuda T, Ohara K, Murakami T, Imai T, Nakagawa S, Okada M, et al. Sodium-glucose cotransporter 2 inhibition with dapagliflozin ameliorates extracellular volume expansion in diabetic kidney disease patients. POJ Diab Obes. 2017;1:1\u20138.","journal-title":"POJ Diab Obes"},{"key":"2753_CR11","doi-asserted-by":"publisher","first-page":"F361","DOI":"10.1152\/ajprenal.00070.2022","volume":"323","author":"T Masuda","year":"2022","unstructured":"Masuda T, Ohara K, Vallon V, Nagata D. SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats. Am J Physiol Ren Physiol. 2022;323:F361\u20139.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2753_CR12","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14360","volume":"8","author":"T Masuda","year":"2020","unstructured":"Masuda T, Muto S, Fukuda K, Watanabe M, Ohara K, Koepsell H, et al. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume. Physiol Rep. 2020;8:e14360.","journal-title":"Physiol Rep"},{"key":"2753_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1287066","volume":"10","author":"K Oka","year":"2023","unstructured":"Oka K, Masuda T, Ohara K, Miura M, Morinari M, Misawa K, et al. Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY trial. Front Med. 2023;10:1287066.","journal-title":"Front Med"},{"key":"2753_CR14","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/0002-9149(87)90615-1","volume":"60","author":"SH Kubo","year":"1987","unstructured":"Kubo SH, Clark M, Laragh JH, Borer JS, Cody RJ. Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. Am J Cardiol. 1987;60:1322\u20138.","journal-title":"Am J Cardiol"},{"key":"2753_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S1388-9842(02)00205-2","volume":"5","author":"DJWV van Kraaij","year":"2003","unstructured":"van Kraaij DJWV, Jansen RWMM, Sweep FCGJ, Hoefnagels WHL. Neurohormonal effects of furosemide withdrawal in elderly heart failure patients with normal systolic function. Eur J Heart Fail. 2003;5:47\u201353.","journal-title":"Eur J Heart Fail"},{"key":"2753_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10741-018-9735-7","volume":"24","author":"J Simonavi\u010dius","year":"2019","unstructured":"Simonavi\u010dius J, Knackstedt C, Brunner-La Rocca H-P. Loop diuretics in chronic heart failure: how to manage congestion?. Heart Fail Rev. 2019;24:17\u201330.","journal-title":"Heart Fail Rev"},{"key":"2753_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMoa1005419","volume":"364","author":"GM Felker","year":"2011","unstructured":"Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797\u2013805.","journal-title":"N Engl J Med"},{"key":"2753_CR18","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","volume":"82","author":"GS Francis","year":"1990","unstructured":"Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724\u20139.","journal-title":"Circulation"},{"key":"2753_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/ehf2.13739","volume":"9","author":"JS Swolinsky","year":"2021","unstructured":"Swolinsky JS, Tuvshinbat E, Leistner DM, Edelmann F, Knebel F, Nerger NP, et al. Discordance between estimated and measured changes in plasma volume among patients with acute heart failure. ESC Heart Fail. 2021;9:66\u201376.","journal-title":"ESC Heart Fail"},{"key":"2753_CR20","first-page":"246","volume":"15","author":"J De Lima","year":"1981","unstructured":"De Lima J, Caillens H, Beaufils M, Ardaillou R. Effects of furosemide-induced plasma volume reduction on plasma antidiuretic hormone in normal and hypertensive subjects. Clin Nephrol. 1981;15:246\u201351.","journal-title":"Clin Nephrol"},{"key":"2753_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/BF01037937","volume":"25","author":"G Cannella","year":"1983","unstructured":"Cannella G, Galva MD, Campanini M, Cesura AM, De Marinis S, Picotti GB. Sequential changes in plasma renin activity and plasma catecholamines in mildly hypertensive patients during acute, furosemide-induced body-fluid loss. Eur J Clin Pharm. 1983;25:299\u2013302.","journal-title":"Eur J Clin Pharm"},{"key":"2753_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1161\/01.CIR.40.3.349","volume":"40","author":"M Davidov","year":"1969","unstructured":"Davidov M, Gavrilovich L, Mroczek W, Finnerty FA. Relation of extracellular fluid volume to arterial pressure during drug-induced saluresis. Circulation. 1969;40:349\u201355.","journal-title":"Circulation"},{"key":"2753_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1161\/01.CIR.57.2.349","volume":"57","author":"J Figueras","year":"1978","unstructured":"Figueras J, Weil MH. Blood volume prior to and following treatment of acute cardiogenic pulmonary edema. Circulation. 1978;57:349\u201355.","journal-title":"Circulation"},{"key":"2753_CR24","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0002-9343(84)90281-X","volume":"76","author":"CJ Schuster","year":"1984","unstructured":"Schuster CJ, Weil MH, Besso J, Carpio M, Henning RJ. Blood volume following diuresis induced by furosemide. Am J Med. 1984;76:585\u201392.","journal-title":"Am J Med"},{"key":"2753_CR25","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/ki.1989.246","volume":"36","author":"NR Loon","year":"1989","unstructured":"Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int. 1989;36:682\u20139.","journal-title":"Kidney Int"},{"key":"2753_CR26","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/nep.13552","volume":"24","author":"K Ohara","year":"2019","unstructured":"Ohara K, Masuda T, Murakami T, Imai T, Yoshizawa H, Nakagawa S, et al. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: a comparison study with furosemide and tolvaptan. Nephrology. 2019;24:904\u201311.","journal-title":"Nephrology"},{"key":"2753_CR27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41440-025-02388-5","volume":"49","author":"T Masuda","year":"2026","unstructured":"Masuda T, Asakura-Kinoshita M, Oka K, Ohara K, Sakai M, Miura M, et al. SGLT2 inhibitor requires co-administration with diuretics to effectively reduce interstitial fluid retention: the DAPA-BODY trial. Hypertens Res. 2026;49:499\u2013507.","journal-title":"Hypertens Res"},{"key":"2753_CR28","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1038\/s41440-026-02572-1","volume":"49","author":"T Tomaru","year":"2026","unstructured":"Tomaru T. Reduction of interstitial fluid retention by combination therapy with dapagliflozin, an SGLT2 inhibitor, and conventional diuretics: comment on a post hoc analysis of the DAPA-BODY trial. Hypertens Res. 2026;49:1778\u201381.","journal-title":"Hypertens Res"},{"key":"2753_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.001918","volume":"4","author":"SC Hung","year":"2015","unstructured":"Hung SC, Lai YS, Kuo KL, Tarng DC. Volume overload and adverse outcomes in chronic kidney disease: clinical observational and animal studies. J Am Heart Assoc. 2015;4:e001918.","journal-title":"J Am Heart Assoc"},{"key":"2753_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/1471-2369-15-189","volume":"15","author":"R Tai","year":"2014","unstructured":"Tai R, Ohashi Y, Mizuiri S, Aikawa A, Sakai K. Association between ratio of measured extracellular volume to expected body fluid volume and renal outcomes in patients with chronic kidney disease: a retrospective single-center cohort study. BMC Nephrol. 2014;15:189.","journal-title":"BMC Nephrol"},{"key":"2753_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1053\/j.ajkd.2013.06.011","volume":"63","author":"YC Tsai","year":"2014","unstructured":"Tsai YC, Tsai JC, Chen SC, Chiu YW, Hwang SJ, Hung CC, et al. Association of fluid overload with kidney disease progression in advanced CKD: a prospective cohort study. Am J Kidney Dis. 2014;63:68\u201375.","journal-title":"Am J Kidney Dis"},{"key":"2753_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13098-020-00545-z","volume":"12","author":"K Ohara","year":"2020","unstructured":"Ohara K, Masuda T, Morinari M, Okada M, Miki A, Nakagawa S, et al. The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease. Diabetol Metab Syndr. 2020;12:37.","journal-title":"Diabetol Metab Syndr"},{"key":"2753_CR33","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1056\/NEJMra1703100","volume":"377","author":"DH Ellison","year":"2017","unstructured":"Ellison DH, Felker GM. Diuretic Treatment in Heart Failure. N Engl J Med. 2017;377:1964\u201375.","journal-title":"N Engl J Med"},{"key":"2753_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF02089953","volume":"14","author":"F Kr\u00fcck","year":"1978","unstructured":"Kr\u00fcck F, Bablok W, Besenfelder E, Betzien G, Kaufmann B. Clinical and pharmacological investigations of the new saluretic azosemid. Eur J Clin Pharm. 1978;14:153\u201361.","journal-title":"Eur J Clin Pharm"},{"key":"2753_CR35","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"2753_CR36","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1172\/JCI102501","volume":"30","author":"MB Strauss","year":"1951","unstructured":"Strauss MB, Davis RK, Rosenbaum JD, Rossmeisl EC. Water diuresis produced during recumbency by the intravenous infusion of isotonic saline solution. J Clin Invest. 1951;30:862\u20138.","journal-title":"J Clin Invest"},{"key":"2753_CR37","first-page":"M597","volume":"36","author":"AA Kaplan","year":"1990","unstructured":"Kaplan AA. A simple and accurate method for prescribing plasma exchange. ASAIO Trans. 1990;36:M597\u20139.","journal-title":"ASAIO Trans"},{"key":"2753_CR38","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1182\/blood.V33.5.649.649","volume":"33","author":"JA Retzlaff","year":"1969","unstructured":"Retzlaff JA, Tauxe WN, Kiely JM, Stroebel CF. Erythrocyte volume, plasma volume, and lean body mass in adult men and women. Blood. 1969;33:649\u201361.","journal-title":"Blood"},{"key":"2753_CR39","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s11255-019-02180-8","volume":"51","author":"T Masuda","year":"2019","unstructured":"Masuda T, Ohara K, Nagayama I, Matsuoka R, Murakami T, Nakagawa S, et al. Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients. Int Urol Nephrol. 2019;51:1623\u20139.","journal-title":"Int Urol Nephrol"},{"key":"2753_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007048","volume":"14","author":"S Tamaki","year":"2021","unstructured":"Tamaki S, Yamada T, Watanabe T, Morita T, Furukawa Y, Kawasaki M, et al. Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: a prospective randomized controlled study. Circ Heart Fail. 2021;14:e007048.","journal-title":"Circ Heart Fail"},{"key":"2753_CR41","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","volume":"142","author":"M Griffin","year":"2020","unstructured":"Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020;142:1028\u201339.","journal-title":"Circulation"},{"key":"2753_CR42","doi-asserted-by":"publisher","first-page":"F958","DOI":"10.1152\/ajprenal.00476.2015","volume":"310","author":"X Huang","year":"2016","unstructured":"Huang X, Dorhout Mees E, Vos P, Hamza S, Braam B. Everything we always wanted to know about furosemide but were afraid to ask. Am J Physiol Ren Physiol. 2016;310:F958\u201371.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2753_CR43","doi-asserted-by":"crossref","unstructured":"Masuda T, Yoshida M, Onaka T, Vallon V, Nagata D. Additive diuretic action of SGLT2 inhibitor and loop diuretic combination avoids body fluid loss by promoting vasopressin-independent compensatory fluid intake: FR-PO554 (Abstract). J Am Soc Nephrol 2024;35:632.","DOI":"10.1681\/ASN.2024c9aryns9"},{"key":"2753_CR44","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","volume":"99","author":"BJ Kraus","year":"2021","unstructured":"Kraus BJ, Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, et al. Characterization and implications of the initial estimated glomerular filtration rate \u2018dip\u2019 upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021;99:750\u201362.","journal-title":"Kidney Int"},{"key":"2753_CR45","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00392-020-01794-8","volume":"110","author":"M Kobayashi","year":"2021","unstructured":"Kobayashi M, Girerd N, Duarte K, Chouihed T, Chikamori T, Pitt B, et al. Estimated plasma volume status in heart failure: clinical implications and future directions. Clin Res Cardiol. 2021;110:1159\u201372.","journal-title":"Clin Res Cardiol"},{"key":"2753_CR46","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1111\/dom.13855","volume":"21","author":"CCJ Dekkers","year":"2019","unstructured":"Dekkers CCJ, Sj\u00f6str\u00f6m CD, Greasley PJ, Cain V, Boulton DW, Heerspink HJL. Effects of the sodium-glucose cotransporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diab Obes Metab. 2019;21:2667\u201373.","journal-title":"Diab Obes Metab"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02753-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02753-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02753-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:02:48Z","timestamp":1785445368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02753-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":46,"alternative-id":["2753"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02753-y","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}